146 related articles for article (PubMed ID: 17620345)
1. Elimination of antiestrogenic effects of active tamoxifen metabolites by glucuronidation.
Zheng Y; Sun D; Sharma AK; Chen G; Amin S; Lazarus P
Drug Metab Dispos; 2007 Oct; 35(10):1942-8. PubMed ID: 17620345
[TBL] [Abstract][Full Text] [Related]
2. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Lim YC; Desta Z; Flockhart DA; Skaar TC
Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
[TBL] [Abstract][Full Text] [Related]
3. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases.
Sun D; Sharma AK; Dellinger RW; Blevins-Primeau AS; Balliet RM; Chen G; Boyiri T; Amin S; Lazarus P
Drug Metab Dispos; 2007 Nov; 35(11):2006-14. PubMed ID: 17664247
[TBL] [Abstract][Full Text] [Related]
4. Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.
Lim YC; Li L; Desta Z; Zhao Q; Rae JM; Flockhart DA; Skaar TC
J Pharmacol Exp Ther; 2006 Aug; 318(2):503-12. PubMed ID: 16690721
[TBL] [Abstract][Full Text] [Related]
5. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants.
Sun D; Chen G; Dellinger RW; Duncan K; Fang JL; Lazarus P
Breast Cancer Res; 2006; 8(4):R50. PubMed ID: 16884532
[TBL] [Abstract][Full Text] [Related]
6. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
Vignon F; Lippman ME; Nawata H; Derocq D; Rochefort H
Cancer Res; 1984 May; 44(5):2084-8. PubMed ID: 6713400
[TBL] [Abstract][Full Text] [Related]
7. Increasing tamoxifen dose in breast cancer patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the antiestrogenic activity score.
Barginear MF; Jaremko M; Peter I; Yu C; Kasai Y; Kemeny M; Raptis G; Desnick RJ
Clin Pharmacol Ther; 2011 Oct; 90(4):605-11. PubMed ID: 21900890
[TBL] [Abstract][Full Text] [Related]
8. [Advances in the research of pharmacogenomics of tamoxifen].
Xiong W; Zhao JJ; Wang L; Jiang XH; Tao XQ
Yao Xue Xue Bao; 2016 Sep; 51(9):1356-67. PubMed ID: 29924509
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen impairs prepubertal mammary development and alters expression of estrogen receptor α (ESR1) and progesterone receptors (PGR).
Tucker HL; Parsons CL; Ellis S; Rhoads ML; Akers RM
Domest Anim Endocrinol; 2016 Jan; 54():95-105. PubMed ID: 26619291
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen metabolite isomer separation and quantification by liquid chromatography-tandem mass spectrometry.
Jaremko M; Kasai Y; Barginear MF; Raptis G; Desnick RJ; Yu C
Anal Chem; 2010 Dec; 82(24):10186-93. PubMed ID: 21086978
[TBL] [Abstract][Full Text] [Related]
11. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites.
Blevins-Primeau AS; Sun D; Chen G; Sharma AK; Gallagher CJ; Amin S; Lazarus P
Cancer Res; 2009 Mar; 69(5):1892-900. PubMed ID: 19244109
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the mechanism of tamoxifen-stimulated breast tumor growth with nonisomerizable analogues of tamoxifen and metabolites.
Wolf DM; Langan-Fahey SM; Parker CJ; McCague R; Jordan VC
J Natl Cancer Inst; 1993 May; 85(10):806-12. PubMed ID: 8487325
[TBL] [Abstract][Full Text] [Related]
13. Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells.
Katzenellenbogen BS; Norman MJ; Eckert RL; Peltz SW; Mangel WF
Cancer Res; 1984 Jan; 44(1):112-9. PubMed ID: 6537799
[TBL] [Abstract][Full Text] [Related]
14. Regulation of estrogen and progestin receptor concentrations in an experimental rat prostatic carcinoma by estrogen, antiestrogen, and progesterone.
Mobbs BG; Johnson IE; DeSombre ER; Toth J; Hughes A
Cancer Res; 1987 May; 47(10):2645-51. PubMed ID: 3552202
[TBL] [Abstract][Full Text] [Related]
15. Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen.
Horwitz KB; Koseki Y; McGuire WL
Endocrinology; 1978 Nov; 103(5):1742-51. PubMed ID: 748014
[TBL] [Abstract][Full Text] [Related]
16. An Antiestrogenic Activity Score for tamoxifen and its metabolites is associated with breast cancer outcome.
de Vries Schultink AH; Alexi X; van Werkhoven E; Madlensky L; Natarajan L; Flatt SW; Zwart W; Linn SC; Parker BA; Wu AH; Pierce JP; Huitema AD; Beijnen JH
Breast Cancer Res Treat; 2017 Feb; 161(3):567-574. PubMed ID: 28005246
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of estrogen and antiestrogen on transforming growth factor gene expression in endometrial adenocarcinoma cells.
Gong Y; Ballejo G; Murphy LC; Murphy LJ
Cancer Res; 1992 Apr; 52(7):1704-9. PubMed ID: 1551100
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.
Maximov PY; McDaniel RE; Fernandes DJ; Bhatta P; Korostyshevskiy VR; Curpan RF; Jordan VC
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25258390
[TBL] [Abstract][Full Text] [Related]
19. Binding characteristics of novel nonsteroidal antiestrogens to the rat uterine estrogen receptors.
Martel C; Provencher L; Li X; St Pierre A; Leblanc G; Gauthier S; Mérand Y; Labrie F
J Steroid Biochem Mol Biol; 1998 Feb; 64(3-4):199-205. PubMed ID: 9605415
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen.
Johnson MD; Zuo H; Lee KH; Trebley JP; Rae JM; Weatherman RV; Desta Z; Flockhart DA; Skaar TC
Breast Cancer Res Treat; 2004 May; 85(2):151-9. PubMed ID: 15111773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
